[Current trends in medical therapy of chronic peripheral obliterating arteriopathies].
Peruzzi
G
G
Tallarida
G
G
Baldoni
F
F
Raimondi
G
G
Grimaldi
I
I
Sangiorgi
M
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D005121:Extremities / Q000098:blood supply*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D013565:Sympatholytics / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D013565:Sympatholytics; D014665:Vasodilator Agents; D011464:Epoprostenol
Prospettive attuali della terapia medica delle arteriopatie obliteranti croniche periferiche.